Rhenman & Partners Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-60,000	Closed	-$6.22M	–	118
2017 Q2	$6.22M	Sell	60,000 -50,000	-45%	-$4.08M	0.89%	44
2017 Q1	$8.63M	Buy	110,000 +30,000	+38%	+$1.86M	1.37%	30
2016 Q4	$3.59M	Sell	80,000 -10,000	-11%	-$491K	0.69%	56
2016 Q3	$5.03M	Buy	90,000 +20,000	+29%	+$1.11M	0.8%	47
2016 Q2	$3.5M	Buy	+70,000	New	+$3.44M	0.62%	60
2015 Q4	–	Sell	-57,000	Closed	-$3.17M	–	100
2015 Q3	$3.17M	Sell	57,000 -9,000	-14%	-$566K	0.51%	62
2015 Q2	$4.02M	Buy	66,000 +21,000	+47%	+$1.2M	0.48%	70
2015 Q1	$2.6M	Buy	45,000 +10,000	+29%	+$670K	0.44%	80
2014 Q4	$2.02M	Buy	+35,000	New	+$1.47M	0.58%	75

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Rhenman & Partners Asset Management's KITE Position: Q3 2017 in Review

Rhenman & Partners Asset Management sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 60,000 shares — an estimated $6.22M sold.

Rhenman & Partners Asset Management first reported a position in KITE in Q4 2014 and held it in 9 quarters. The position peaked at $8.63M in Q1 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Rhenman & Partners Asset Management reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Rhenman & Partners Asset Management sold 60,000 Kite Pharma, Inc. shares in Q3 2017, an estimated $6.22M.
Rhenman & Partners Asset Management first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 9 quarters.
Rhenman & Partners Asset Management's Kite Pharma, Inc. position peaked at $8.63M in Q1 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.